Hovione And iBET Announce The Establishment Of ViSync Technologies: A Venture In Cell And Gene Therapy Solutions

Commitment to partnership and joint innovation for cell and gene therapies

Hovione, the specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a private not-for-profit research-intensive SME in the area of Biotechnology and Life Sciences, are proud to announce the official establishment of ViSync Technologies as a jointly owned venture.

The creation of this new company, headquartered in the Lisbon area of Portugal, illustrates the parent companies´ commitment to partnership and joint innovation. ViSync will aim to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy space, leveraging Hovione's extensive expertise in pharmaceutical development, Particle Engineering and industrialization of pharmaceutical technologies and iBET's cutting-edge research in biotechnological sciences. One of the first focus areas of ViSync will be to develop technologies that improve delivery and stabilization of new modality therapies.

"We are delighted to join forces with iBET - a leading R&D organization in Biotechnology and Life Sciences – in the establishment of ViSync.” says Jean-Luc Herbeaux, Hovione’s CEO. “By combining Hovione´s expertise in drug formulation, manufacturing process development and scale up with iBET´s broad understanding of new modalities, we aim to devise new solutions to help pharma companies launch innovative medicines and improve health outcomes for patients.”

“The creation of ViSync marks a significant milestone for iBET.” says Paula Alves, CEO of iBET. “By combining our cutting-edge biotechnological research in the cell and gene therapy fields with Hovione’s extensive pharmaceutical development expertise, we are well-positioned to develop innovative approaches for targeted delivery and stabilization of new modality therapies. We are excited about the potential of ViSync to drive substantial advancements and deliver significant benefits to patients worldwide.”